1 recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Recruiting 1 |
Follow IBI3003: new trials by email Literature Review of IBI3003 trials Research Report on IBI3003
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 Pomalidomide Capsules, Bortezomib for Injection, Daratumumab Injection (Subcutaneous Injection) - Relapsed or Refractory Multiple Myeloma | Phase 3 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 255 | 2026-06-11 | 2026-09-17 |
Multiple Myeloma (1) · Recurrence (1)
Innovent Biologics (Suzhou) Co. Ltd. (1)
China (1)